French veterinary laboratory Ceva Santé Animale, backed by Nixen, Euromezzanine and Sagard, has mandated Lazard to explore the possibility of a sale in the first half of 2014.
Calucem reports a turnover of EUR 58m, with an EBITDA of EUR 16m
Should Apex make a firm offer, Cinven would have to significantly up its own bid for the fund administrator
Third exit announced by Lonsdale this year, and the second from its 2016 fund
Paris-based private equity firm is exploring options around a dual-track process